Hepatic <i>IFNL4</i> Gene Activation in Hepatocellular Carcinoma Patients with Regard to Etiology
Hepatocellular carcinoma (HCC) is a malignancy with a leading lethality. The etiology is quite diverse, ranging from viral infections to metabolic disorders or intoxications, and associates with specific somatic mutational patterns and specific host immunological phenotypes. Particularly, hepatitis...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-07-01
|
| Series: | International Journal of Molecular Sciences |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1422-0067/22/15/7803 |
| _version_ | 1797525568196968448 |
|---|---|
| author | Henriette Huschka Sabine Mihm |
| author_facet | Henriette Huschka Sabine Mihm |
| author_sort | Henriette Huschka |
| collection | DOAJ |
| description | Hepatocellular carcinoma (HCC) is a malignancy with a leading lethality. The etiology is quite diverse, ranging from viral infections to metabolic disorders or intoxications, and associates with specific somatic mutational patterns and specific host immunological phenotypes. Particularly, hepatitis C virus (HCV)-infected liver is featured by an activation of interferon (IFN)-stimulated genes (ISGs; IFN signature), which we suppose is driven by type III <i>IFNL4</i>. Taking advantage of the TCGA collection of HCC patients of various different etiologies, this study aimed at validating our previous findings on hepatic <i>IFNL4</i> gene activation in HCV infection in an independent and larger cohort of patients with advanced liver disease. In a cohort of <i>n</i> = 377 cases, the entirety of the sequencing data was used to assess the <i>IFNL</i> genotypes, and the cases were stratified for etiology. The number of <i>IFNL4</i> transcripts within nonmalignant and malignant tissues was found to be more abundant in patients with HCV or HCV/HBV infections when compared to other risk factors. Moreover, in patients with HCV infection as a risk factor, a close, positive relationship was found between ISG activation and the number of functional <i>IFNL4</i> transcripts. Data on this independent TCGA sample support the concept of an <i>IFNL4</i>-dependent HCV-driven activation of hepatic ISGs. In addition to that, they add to the understanding of etiology-related host immunological phenotypes in HCC. |
| first_indexed | 2024-03-10T09:15:41Z |
| format | Article |
| id | doaj.art-32c2f679adbe4881a754f7399006e134 |
| institution | Directory Open Access Journal |
| issn | 1661-6596 1422-0067 |
| language | English |
| last_indexed | 2024-03-10T09:15:41Z |
| publishDate | 2021-07-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | International Journal of Molecular Sciences |
| spelling | doaj.art-32c2f679adbe4881a754f7399006e1342023-11-22T05:38:37ZengMDPI AGInternational Journal of Molecular Sciences1661-65961422-00672021-07-012215780310.3390/ijms22157803Hepatic <i>IFNL4</i> Gene Activation in Hepatocellular Carcinoma Patients with Regard to EtiologyHenriette Huschka0Sabine Mihm1Department of Gastroenterology, Gastrointestinal Oncology and Endocrinology, University Medical Center, 37075 Goettingen, GermanyDepartment of Gastroenterology, Gastrointestinal Oncology and Endocrinology, University Medical Center, 37075 Goettingen, GermanyHepatocellular carcinoma (HCC) is a malignancy with a leading lethality. The etiology is quite diverse, ranging from viral infections to metabolic disorders or intoxications, and associates with specific somatic mutational patterns and specific host immunological phenotypes. Particularly, hepatitis C virus (HCV)-infected liver is featured by an activation of interferon (IFN)-stimulated genes (ISGs; IFN signature), which we suppose is driven by type III <i>IFNL4</i>. Taking advantage of the TCGA collection of HCC patients of various different etiologies, this study aimed at validating our previous findings on hepatic <i>IFNL4</i> gene activation in HCV infection in an independent and larger cohort of patients with advanced liver disease. In a cohort of <i>n</i> = 377 cases, the entirety of the sequencing data was used to assess the <i>IFNL</i> genotypes, and the cases were stratified for etiology. The number of <i>IFNL4</i> transcripts within nonmalignant and malignant tissues was found to be more abundant in patients with HCV or HCV/HBV infections when compared to other risk factors. Moreover, in patients with HCV infection as a risk factor, a close, positive relationship was found between ISG activation and the number of functional <i>IFNL4</i> transcripts. Data on this independent TCGA sample support the concept of an <i>IFNL4</i>-dependent HCV-driven activation of hepatic ISGs. In addition to that, they add to the understanding of etiology-related host immunological phenotypes in HCC.https://www.mdpi.com/1422-0067/22/15/7803hepatitis C virus (HCV)hepatocellular carcinoma (HCC)interferon-stimulated gene (ISG)interferon lambda 4 (<i>IFNL4</i>)rs368234815rs11322783 |
| spellingShingle | Henriette Huschka Sabine Mihm Hepatic <i>IFNL4</i> Gene Activation in Hepatocellular Carcinoma Patients with Regard to Etiology International Journal of Molecular Sciences hepatitis C virus (HCV) hepatocellular carcinoma (HCC) interferon-stimulated gene (ISG) interferon lambda 4 (<i>IFNL4</i>) rs368234815 rs11322783 |
| title | Hepatic <i>IFNL4</i> Gene Activation in Hepatocellular Carcinoma Patients with Regard to Etiology |
| title_full | Hepatic <i>IFNL4</i> Gene Activation in Hepatocellular Carcinoma Patients with Regard to Etiology |
| title_fullStr | Hepatic <i>IFNL4</i> Gene Activation in Hepatocellular Carcinoma Patients with Regard to Etiology |
| title_full_unstemmed | Hepatic <i>IFNL4</i> Gene Activation in Hepatocellular Carcinoma Patients with Regard to Etiology |
| title_short | Hepatic <i>IFNL4</i> Gene Activation in Hepatocellular Carcinoma Patients with Regard to Etiology |
| title_sort | hepatic i ifnl4 i gene activation in hepatocellular carcinoma patients with regard to etiology |
| topic | hepatitis C virus (HCV) hepatocellular carcinoma (HCC) interferon-stimulated gene (ISG) interferon lambda 4 (<i>IFNL4</i>) rs368234815 rs11322783 |
| url | https://www.mdpi.com/1422-0067/22/15/7803 |
| work_keys_str_mv | AT henriettehuschka hepaticiifnl4igeneactivationinhepatocellularcarcinomapatientswithregardtoetiology AT sabinemihm hepaticiifnl4igeneactivationinhepatocellularcarcinomapatientswithregardtoetiology |